Graham C. Ellis

Efficacy and safety of adding the dipeptidyl peptidase-4 inhibitor alogliptin to metformin therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy: a multicentre, randomised, double-blind, placebo-controlled study

Michael A. Nauck, Graham C. Ellis, P. Fleck et al. · International Journal of Clinical Practice · 2008 · 203 citations · Full text

Odanacatib for the treatment of postmenopausal osteoporosis: results of the LOFT multicentre, randomised, double-blind, placebo-controlled trial and LOFT Extension study

Michael R. McClung, Michelle L. O’Donoghue, Socrates E. Papapoulos et al. · The Lancet Diabetes & Endocrinology · 2019 · 164 citations

Bone Disease, Osteopathy, Loft Extension Study +10

Alogliptin as a third oral antidiabetic drug in patients with type 2 diabetes and inadequate glycaemic control on metformin and pioglitazone: a 52‐week, randomized, double‐blind, active‐controlled, parallel‐group study

Emanuele Bosi, Graham C. Ellis, Carol Wilson et al. · Diabetes Obesity and Metabolism · 2011 · 85 citations

Substantial fibrin amyloidogenesis in type 2 diabetes assessed using amyloid-selective fluorescent stains

Etheresia Pretorius, Martin Pagé, Lize Engelbrecht et al. · Cardiovascular Diabetology · 2017 · 75 citations · Full text

The safety of osteoporosis medication

F. S. Hough, Susan L. Brown, Bilkish Cassim et al. · South African Medical Journal · 2013 · 22 citations · Full text

Bone Disease, Bone Health, Osteoporosis Medications +9